Director, HTA, Value & Evidence (HV&E) - Rare Disease (9-month secondment)

Pfizer•New York City, NY

23h•Hybrid

About The Position

As a leading biopharmaceutical company, Pfizer is dedicated to the discovery and delivery of high value therapies across a variety of disease areas. It is our mission to bring innovative medicines to patients that significantly improve their lives, and our priority is to ensure patients have access to these medicines. The Health Technology Assessment (HTA), Value & Evidence (HV&E) team is responsible for ensuring patients have affordable, timely access to medicines and vaccines by advancing innovative value and evidence solutions to inform healthcare decision-making. The Director, HTA, Value & Evidence (HV&E) – Rare Disease secondee will support the strategic goals of the Rare Disease Division by driving optimal patient access for Hympavzi (marstacimab), noninhibitor indication. This role influences global business objectives by guiding strategic evidence development to ensure optimal patient access for Hympavzi (marstacimab). The HV&E Director will be responsible for developing and executing against the global evidence generation strategy, including direct oversight of evidence generation activities and dissemination of technical deliverables. This position will be part of Pfizer’s dynamic HV&E team and will have the important role of managing health economics and outcomes research (HEOR) to generate data to support patient access to for Hympavzi (marstacimab). This position will be working closely with the Rare Disease cross-functional team (e.g., access strategy/pricing, medical, clinical, commercial, etc.) and country teams to foster a culture that promotes innovation and thrives on doing better for Pfizer’s patients and society in general.

Requirements

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Graduate degree required (e.g. MSc, MPH, PhD, DrPH)
7+ years of experience with MSc/MPH/MBA degree; 5+ years with PharmD/PhD/DrPH in HEOR or relevant related fields (health economics, epidemiology, health services research, or other research-focused public health field)
Expertise in HEOR strategy, evidence development, fundamental health services research methods and tools, including health economic modeling, patient-reported outcomes, statistics, and real-world evidence studies including technical and methodological aspects of registries and observational study design, implementation, analysis and interpretation.
Capable of independently managing complex non-interventional study projects
Knowledge and understanding of drug development process
Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers
Excellent oral and written English communication skills
Demonstrated ability to assess anticipated value for projects/programs to ensure alignment to business priorities and prioritize accordingly
An “execution mindset” focused on getting things done quickly and simply
Strong project management abilities (contracting, budgeting, vendor management) essential.
Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities and expertise in stakeholder engagement
Leadership in cross-functional teams (e.g. influence medical, clinical, and commercial teams constructively and without conflict); strategic thinking, and ability to guide junior team members
Skilled in functioning within a matrix organization
Organized and detail oriented with the ability to anticipate needs and to work proactively to prioritize & address/resolve
Change oriented, comfortable responding to unexpected demands with tight timelines
This position requires permanent work authorization in the United States.

Nice To Haves

Knowledge and experience in the Hemophilia/Rare Disease therapeutical area
Experience with HTA organizations such as NICE, CADTH, PBAC, ICER and other HTA groups
Knowledge of industry trends (e.g. IPAY, EU HTA Regulation)
Demonstrated publication history in venerable peer reviewed journals
Experience in the biotech/pharmaceutical industry
Experience in supporting a global launch

Responsibilities

Lead the development of the evidence generation strategy to support the value of Hympavzi (marstacimab), in close partnership with the cross-functional matrix team (e.g., medical, commercial, access strategy/pricing, statistics, clinical).
Lead the coordination of input from local country/regional teams on evidence needs and ensure that the input is appropriately incorporated into the evidence strategy to support global market access needs at launch and through lifecycle.
Lead the design and execution of global HEOR studies (e.g., network meta-analyses, non-interventional studies, economic models) from concept through publication.
Lead the timely development of launch deliverables including value & evidence strategy, global value dossiers/AMCP/JCA dossiers, systematic literature reviews, economic models, and innovative tools to successfully support reimbursement and access requirements in partnership with the regions/countries.
Develop patient-reported outcomes strategy and incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence aligned with overall asset strategy and to ensure global reimbursement and access requirements.
Provide strategic input into clinical trial designs (eg, patient populations, comparators, endpoints) and analysis to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers.
Partner with internal stakeholders to ensure appropriate customer facing dissemination of HEOR materials per regulatory guidance and internal SOPs.
Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, and various academic and community oncology settings to support asset strategies.